Treatments for hepatitis C are notoriously expensive, and the price for Harvoni is no different. Patients typically take Harvoni for 12 weeks, and the list price for a one-month supply runs at $31,500 for 28 tablets—or $1,125 per tablet—making Harvoni the ninth most expensive drug in the United States. We’re not kidding.
Epclusa Latest News
Get the latest updates on this drug from the GoodRx medical team
The FDA has issued a drug safety alert for direct-acting antivirals used to treat Hepatitis C. They warn that using direct-acting antivirals such as Sovaldi, Harvoni, or Zepatier can cause a reactivation of Hepatitis B in patients who have been previously infected with the virus.
The FDA gained knowledge about the reactivation of hepatitis B occurring from direct-acting antivirals through reported incidents and published literature. See More
More and more new hepatitis C medications are being approved at a faster rate than ever thanks to the FDA’s Priority Review program. New approvals over the past few years include Sovaldi, Harvoni, Viekira Pak.
This is great news, as it means there are more effective options than ever out there to treat hepatitis C—and the most recent addition, Epclusa (sofosbuvir/velpatasvir), is another first of its kind treatment. See More